Medical Therapy and Recurrent Ischemic Events in High Risk Patients Surviving their Myocardial Infarction for at Least 12 Months: Comparison ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-12

AUTHORS

Uwe Zeymer, Katrin Riedel, Michael Hahn

ABSTRACT

INTRODUCTION: Data about treatments and recurrent ischemic events in patients surviving their most recent myocardial infarction event-free for at least 12 months are scarce. METHODS: In a retrospective data analysis, charts of patients who had a myocardial infarction 1-3 years ago with an event-free period of at least 12 months after the index event and at least one high risk factor were centrally collected and analyzed. Here we compare patients with ST elevation myocardial infarction (STEMI) versus non-ST elevation myocardial infarction (NSTEMI). RESULTS: A total of 666 patients, 342 with STEMI and 324 with NSTEMI, were included. Revascularization procedures for the index event were performed in 89% of patients with STEMI and 72% of patients with NSTEMI. About 62% of patients were still on dual antiplatelet therapy after 12 months, predominantly with aspirin and clopidogrel. This rate declined to 30% after 18 months. Patients with STEMI had a higher mortality (19% versus 13%, p = 0.04) and major adverse cardiovascular and cerebrovascular event rate (MACCE; 33% versus 23%, p = 0.03) during follow-up up to 36 months, while there were no significant differences with respect to recurrent myocardial infarction or stroke. The number of high risk factors was closely linked to the rate of MACCE at follow up. CONCLUSIONS: Patients surviving their myocardial infarction without any further event during the first 12 months have a high rate of recurrent ischemic events in both STEMI and NSTEMI cases during subsequent follow-up. Therefore, secondary prevention therapies should be continued even one year after myocardial infarction, which might improve outcomes. More... »

PAGES

273-280

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40119-017-0093-7

DOI

http://dx.doi.org/10.1007/s40119-017-0093-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1086031003

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28616861


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Stiftung Institut f\u00fcr Herzinfarktforschung", 
          "id": "https://www.grid.ac/institutes/grid.488379.9", 
          "name": [
            "Klinikum Ludwigshafen and Institut f\u00fcr Herzinfarktforschung, Ludwigshafen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zeymer", 
        "givenName": "Uwe", 
        "id": "sg:person.01206257120.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01206257120.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.487186.4", 
          "name": [
            "Astra Zeneca Germany GmbH, Wedel, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Riedel", 
        "givenName": "Katrin", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.487186.4", 
          "name": [
            "Astra Zeneca Germany GmbH, Wedel, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hahn", 
        "givenName": "Michael", 
        "id": "sg:person.013366344217.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013366344217.67"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1136/heart.83.3.361", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005328571"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ahj.2012.12.020", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007400830"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehs289", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011642153"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.2010.1322", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012246124"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehl196", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018098636"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1200933", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023853326"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehq326", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027987559"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehq326", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027987559"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehs215", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030848257"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehv320", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031315483"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmjopen-2013-004425", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036300501"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehl317", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036770018"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehi002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037075164"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/heartjnl-2012-301700", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039003144"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/heartjnl-2016-309509", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040934659"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehu505", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041236095"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1500857", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041478315"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00059-014-4161-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043027881", 
          "https://doi.org/10.1007/s00059-014-4161-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehv443", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047965142"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-12", 
    "datePublishedReg": "2017-12-01", 
    "description": "INTRODUCTION: Data about treatments and recurrent ischemic events in patients surviving their most recent myocardial infarction event-free for at least 12\u00a0months are scarce.\nMETHODS: In a retrospective data analysis, charts of patients who had a myocardial infarction 1-3\u00a0years ago with an event-free period of at least 12\u00a0months after the index event and at least one high risk factor were centrally collected and analyzed. Here we compare patients with ST elevation myocardial infarction (STEMI) versus non-ST elevation myocardial infarction (NSTEMI).\nRESULTS: A total of 666 patients, 342 with STEMI and 324 with NSTEMI, were included. Revascularization procedures for the index event were performed in 89% of patients with STEMI and 72% of patients with NSTEMI. About 62% of patients were still on dual antiplatelet therapy after 12\u00a0months, predominantly with aspirin and clopidogrel. This rate declined to 30% after 18\u00a0months. Patients with STEMI had a higher mortality (19% versus 13%, p\u00a0=\u00a00.04) and major adverse cardiovascular and cerebrovascular event rate (MACCE; 33% versus 23%, p\u00a0=\u00a00.03) during follow-up up to 36\u00a0months, while there were no significant differences with respect to recurrent myocardial infarction or stroke. The number of high risk factors was closely linked to the rate of MACCE at follow up.\nCONCLUSIONS: Patients surviving their myocardial infarction without any further event during the first 12\u00a0months have a high rate of recurrent ischemic events in both STEMI and NSTEMI cases during subsequent follow-up. Therefore, secondary prevention therapies should be continued even one\u00a0year after myocardial infarction, which might improve outcomes.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s40119-017-0093-7", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1050274", 
        "issn": [
          "2193-8261", 
          "2193-6544"
        ], 
        "name": "Cardiology and Therapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "6"
      }
    ], 
    "name": "Medical Therapy and Recurrent Ischemic Events in High Risk Patients Surviving their Myocardial Infarction for at Least 12 Months: Comparison of Patients with ST Elevation Versus Non-ST Elevation Myocardial Infarction", 
    "pagination": "273-280", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "280f4f52508c66f65bd440c62de8b3df4a8fd46544ec69b792e986f0da3ffe5d"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28616861"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101634495"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40119-017-0093-7"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1086031003"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40119-017-0093-7", 
      "https://app.dimensions.ai/details/publication/pub.1086031003"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:50", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89786_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs40119-017-0093-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40119-017-0093-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40119-017-0093-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40119-017-0093-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40119-017-0093-7'


 

This table displays all metadata directly associated to this object as RDF triples.

140 TRIPLES      21 PREDICATES      47 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40119-017-0093-7 schema:about anzsrc-for:11
2 anzsrc-for:1102
3 schema:author N5e88e6377e304a459d3dd4bdde6c318c
4 schema:citation sg:pub.10.1007/s00059-014-4161-7
5 https://doi.org/10.1001/jama.2010.1322
6 https://doi.org/10.1016/j.ahj.2012.12.020
7 https://doi.org/10.1056/nejmoa1200933
8 https://doi.org/10.1056/nejmoa1500857
9 https://doi.org/10.1093/eurheartj/ehi002
10 https://doi.org/10.1093/eurheartj/ehl196
11 https://doi.org/10.1093/eurheartj/ehl317
12 https://doi.org/10.1093/eurheartj/ehq326
13 https://doi.org/10.1093/eurheartj/ehs215
14 https://doi.org/10.1093/eurheartj/ehs289
15 https://doi.org/10.1093/eurheartj/ehu505
16 https://doi.org/10.1093/eurheartj/ehv320
17 https://doi.org/10.1093/eurheartj/ehv443
18 https://doi.org/10.1136/bmjopen-2013-004425
19 https://doi.org/10.1136/heart.83.3.361
20 https://doi.org/10.1136/heartjnl-2012-301700
21 https://doi.org/10.1136/heartjnl-2016-309509
22 schema:datePublished 2017-12
23 schema:datePublishedReg 2017-12-01
24 schema:description INTRODUCTION: Data about treatments and recurrent ischemic events in patients surviving their most recent myocardial infarction event-free for at least 12 months are scarce. METHODS: In a retrospective data analysis, charts of patients who had a myocardial infarction 1-3 years ago with an event-free period of at least 12 months after the index event and at least one high risk factor were centrally collected and analyzed. Here we compare patients with ST elevation myocardial infarction (STEMI) versus non-ST elevation myocardial infarction (NSTEMI). RESULTS: A total of 666 patients, 342 with STEMI and 324 with NSTEMI, were included. Revascularization procedures for the index event were performed in 89% of patients with STEMI and 72% of patients with NSTEMI. About 62% of patients were still on dual antiplatelet therapy after 12 months, predominantly with aspirin and clopidogrel. This rate declined to 30% after 18 months. Patients with STEMI had a higher mortality (19% versus 13%, p = 0.04) and major adverse cardiovascular and cerebrovascular event rate (MACCE; 33% versus 23%, p = 0.03) during follow-up up to 36 months, while there were no significant differences with respect to recurrent myocardial infarction or stroke. The number of high risk factors was closely linked to the rate of MACCE at follow up. CONCLUSIONS: Patients surviving their myocardial infarction without any further event during the first 12 months have a high rate of recurrent ischemic events in both STEMI and NSTEMI cases during subsequent follow-up. Therefore, secondary prevention therapies should be continued even one year after myocardial infarction, which might improve outcomes.
25 schema:genre research_article
26 schema:inLanguage en
27 schema:isAccessibleForFree true
28 schema:isPartOf N380b80fa2bb04248aa2ddc150491b6b6
29 Ne358c00190634275bfcd51ad50016731
30 sg:journal.1050274
31 schema:name Medical Therapy and Recurrent Ischemic Events in High Risk Patients Surviving their Myocardial Infarction for at Least 12 Months: Comparison of Patients with ST Elevation Versus Non-ST Elevation Myocardial Infarction
32 schema:pagination 273-280
33 schema:productId N2b62de1e03ff41278199eb1ddc118c68
34 N7513df67ad264cee9349b753248592e7
35 Na5f70f5b5bee41e5bce2fe575369c190
36 Ndc2abb7a8bb445028565d2a304029a89
37 Nff096008be1141f09238019be4ff0c41
38 schema:sameAs https://app.dimensions.ai/details/publication/pub.1086031003
39 https://doi.org/10.1007/s40119-017-0093-7
40 schema:sdDatePublished 2019-04-11T09:50
41 schema:sdLicense https://scigraph.springernature.com/explorer/license/
42 schema:sdPublisher N94a7e4553172476f8ef716c603f461c2
43 schema:url https://link.springer.com/10.1007%2Fs40119-017-0093-7
44 sgo:license sg:explorer/license/
45 sgo:sdDataset articles
46 rdf:type schema:ScholarlyArticle
47 N19d3097408134781a52f67544be9be66 rdf:first N1e22df78a73a42a4b4efee6b152d772a
48 rdf:rest N61270535c5e147219014867ca8770550
49 N1e22df78a73a42a4b4efee6b152d772a schema:affiliation https://www.grid.ac/institutes/grid.487186.4
50 schema:familyName Riedel
51 schema:givenName Katrin
52 rdf:type schema:Person
53 N2b62de1e03ff41278199eb1ddc118c68 schema:name pubmed_id
54 schema:value 28616861
55 rdf:type schema:PropertyValue
56 N380b80fa2bb04248aa2ddc150491b6b6 schema:issueNumber 2
57 rdf:type schema:PublicationIssue
58 N5e88e6377e304a459d3dd4bdde6c318c rdf:first sg:person.01206257120.28
59 rdf:rest N19d3097408134781a52f67544be9be66
60 N61270535c5e147219014867ca8770550 rdf:first sg:person.013366344217.67
61 rdf:rest rdf:nil
62 N7513df67ad264cee9349b753248592e7 schema:name dimensions_id
63 schema:value pub.1086031003
64 rdf:type schema:PropertyValue
65 N94a7e4553172476f8ef716c603f461c2 schema:name Springer Nature - SN SciGraph project
66 rdf:type schema:Organization
67 Na5f70f5b5bee41e5bce2fe575369c190 schema:name nlm_unique_id
68 schema:value 101634495
69 rdf:type schema:PropertyValue
70 Ndc2abb7a8bb445028565d2a304029a89 schema:name doi
71 schema:value 10.1007/s40119-017-0093-7
72 rdf:type schema:PropertyValue
73 Ne358c00190634275bfcd51ad50016731 schema:volumeNumber 6
74 rdf:type schema:PublicationVolume
75 Nff096008be1141f09238019be4ff0c41 schema:name readcube_id
76 schema:value 280f4f52508c66f65bd440c62de8b3df4a8fd46544ec69b792e986f0da3ffe5d
77 rdf:type schema:PropertyValue
78 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
79 schema:name Medical and Health Sciences
80 rdf:type schema:DefinedTerm
81 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
82 schema:name Cardiorespiratory Medicine and Haematology
83 rdf:type schema:DefinedTerm
84 sg:journal.1050274 schema:issn 2193-6544
85 2193-8261
86 schema:name Cardiology and Therapy
87 rdf:type schema:Periodical
88 sg:person.01206257120.28 schema:affiliation https://www.grid.ac/institutes/grid.488379.9
89 schema:familyName Zeymer
90 schema:givenName Uwe
91 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01206257120.28
92 rdf:type schema:Person
93 sg:person.013366344217.67 schema:affiliation https://www.grid.ac/institutes/grid.487186.4
94 schema:familyName Hahn
95 schema:givenName Michael
96 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013366344217.67
97 rdf:type schema:Person
98 sg:pub.10.1007/s00059-014-4161-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043027881
99 https://doi.org/10.1007/s00059-014-4161-7
100 rdf:type schema:CreativeWork
101 https://doi.org/10.1001/jama.2010.1322 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012246124
102 rdf:type schema:CreativeWork
103 https://doi.org/10.1016/j.ahj.2012.12.020 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007400830
104 rdf:type schema:CreativeWork
105 https://doi.org/10.1056/nejmoa1200933 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023853326
106 rdf:type schema:CreativeWork
107 https://doi.org/10.1056/nejmoa1500857 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041478315
108 rdf:type schema:CreativeWork
109 https://doi.org/10.1093/eurheartj/ehi002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037075164
110 rdf:type schema:CreativeWork
111 https://doi.org/10.1093/eurheartj/ehl196 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018098636
112 rdf:type schema:CreativeWork
113 https://doi.org/10.1093/eurheartj/ehl317 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036770018
114 rdf:type schema:CreativeWork
115 https://doi.org/10.1093/eurheartj/ehq326 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027987559
116 rdf:type schema:CreativeWork
117 https://doi.org/10.1093/eurheartj/ehs215 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030848257
118 rdf:type schema:CreativeWork
119 https://doi.org/10.1093/eurheartj/ehs289 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011642153
120 rdf:type schema:CreativeWork
121 https://doi.org/10.1093/eurheartj/ehu505 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041236095
122 rdf:type schema:CreativeWork
123 https://doi.org/10.1093/eurheartj/ehv320 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031315483
124 rdf:type schema:CreativeWork
125 https://doi.org/10.1093/eurheartj/ehv443 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047965142
126 rdf:type schema:CreativeWork
127 https://doi.org/10.1136/bmjopen-2013-004425 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036300501
128 rdf:type schema:CreativeWork
129 https://doi.org/10.1136/heart.83.3.361 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005328571
130 rdf:type schema:CreativeWork
131 https://doi.org/10.1136/heartjnl-2012-301700 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039003144
132 rdf:type schema:CreativeWork
133 https://doi.org/10.1136/heartjnl-2016-309509 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040934659
134 rdf:type schema:CreativeWork
135 https://www.grid.ac/institutes/grid.487186.4 schema:alternateName AstraZeneca (Germany)
136 schema:name Astra Zeneca Germany GmbH, Wedel, Germany
137 rdf:type schema:Organization
138 https://www.grid.ac/institutes/grid.488379.9 schema:alternateName Stiftung Institut für Herzinfarktforschung
139 schema:name Klinikum Ludwigshafen and Institut für Herzinfarktforschung, Ludwigshafen, Germany
140 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...